Navigation Links
ADVENTRX Completes Acquisition of SynthRx
Date:4/11/2011

r results may differ materially from those expressed or implied by the forward-looking statements in this press release due to a number of risks and uncertainties, including, without limitation: delays associated with the development of ANX-188, including identifying and qualifying contract manufacturers and contract research organizations and developing and reaching agreement with FDA regarding a pivotal phase 3 clinical study, including the potential for FDA to require additional nonclinical or clinical work prior to initiating the currently contemplated phase 3 clinical trial of ANX-188; the potential that the cost and time required to develop ANX-188 are greater than ADVENTRX's current expectations; the risk that clinical study results do not support the safety and efficacy or the commercial viability of ANX-188; the potential that ADVENTRX's stockholders do not approve the issuance of the milestone-related shares and ADVENTRX must pay the cash value of those shares, to the extent the milestones are achieved; the risk that ADVENTRX may not be able to integrate SynthRx's assets successfully into its operations or that it may incur unexpected costs and disruptions to its business as a result of such integration; the risk that the neither the FDA nor any other regulatory agency approves a product based on ANX-188 or any other product candidate developed using technology acquired from SynthRx on a timely basis, or at all; the potential that ADVENTRX may require substantial additional funding to develop and commercialize ANX-188, and the risk that ADVENTRX may not be able to raise sufficient capital when needed, or at all; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.  

You are cautioned not to place undue reliance on for
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015  Impax Laboratories, Inc. (NASDAQ: IPXL ) ... roles, appointing  Donna M. Hughes, as Senior Vice President, ... Senior Vice President, Chief Compliance Officer. Both Ms. Hughes ... Chief Executive Officer, Fred Wilkinson . ... the Impax team," said Fred Wilkinson , President ...
(Date:5/4/2015)...  Makindus, Inc. a specialty pharmaceutical development company focused ... (EMA) has granted orphan drug designation for their lead ... "We are extremely pleased to now have orphan ... place for Europe . This complements ... United States for which orphan designation has ...
(Date:5/4/2015)... , May 4, 2015  By looking ... possible to distinguish between two very different conditions ... Theodore Henderson , MD, PhD., a ... complex cases, this study can help ... and therefore treatment options, for Post-Traumatic Stress Disorder ...
Breaking Medicine Technology:Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3European Medicines Agency (EMA) Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 3
... DIEGO, Dec. 1 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ... completed preclinical study has affirmed the bioequivalence and comparable ... Pharmaceuticals, ADVENTRX,s partner for ANX-514 in South Korea, independently ... "Our independent confirmation of the bioequivalence and comparable overall ...
... , REDWOOD CITY, Calif., Dec. 1 Codexis, Inc. today ... its second agreement this year with Teva Pharmaceutical Industries Ltd., ... covers three undisclosed pharmaceutical products. Codexis announced an earlier ... agreement, Teva will use Codexis biocatalysis technology for key process ...
Cached Medicine Technology:ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 2ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 3Codexis Expands Collaboration with Teva 2
(Date:5/5/2015)... BioFit Engineered Products , a ... models from its two latest lines at NeoCon 2015, ... Chicago. Headlining the company’s exhibit will be new Pro ... as well as the unveiling of the fifth model ... Ed Metzger will deliver in-booth presentations each day of ...
(Date:5/5/2015)... NY (PRWEB) May 05, 2015 With the ... clothing and enjoying the feel of warm breezes on bare ... to strategies on how to look their best in shorts, ... “More and more people are turning to laser treatments for ... aesthetician of Simply Posh Aesthetic Spa . “They're all ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 “We currently have larger ... states Marta Phillips, owner of SunGrubbies.com. “We felt it was ... to find a fashionable sun hat in an extra large size ... event.” , Fashionable derby sun hats such as the ... brim are now available in an extra large size , ...
(Date:5/5/2015)... San Francisco, Calif. (PRWEB) May 05, 2015 ... available online but these have focused primarily on personal ... the National Directory of Insurance (NDOI.com) has ... licensed insurance agents in the U.S. to present their ... public marketplace. , The result is significant and two-fold. ...
(Date:5/5/2015)... York, NY (PRWEB) May 05, 2015 No ... The Centers for Disease Control and Prevention cite ... effects our everyday life: “Poor indoor air quality (pollution) can ... to chronic heart and lung problems and cancer.” , Toxic ... swallow them in contaminated food or water, or in some ...
Breaking Medicine News(10 mins):Health News:BioFit to Introduce New Models from Latest Specialized Ergonomic Seating Lines at NeoCon 2015 2Health News:BioFit to Introduce New Models from Latest Specialized Ergonomic Seating Lines at NeoCon 2015 3Health News:Laser Hair Removal: Tips for Summertime Grooming 2Health News:Laser Hair Removal: Tips for Summertime Grooming 3Health News:SunGrubbies.com, a Leading Online Retailer of Sun Protection Products, Launches Their New Extra Large Size Fashion Sun Hats Collection 2Health News:NDOI Launch Brings Commercial Insurance Online for the First Time 2Health News:NDOI Launch Brings Commercial Insurance Online for the First Time 3Health News:revitaRUGS is Offering Area Rug Cleaning Discounts in Support of Asthma and Allergy Awareness Month This May 2Health News:revitaRUGS is Offering Area Rug Cleaning Discounts in Support of Asthma and Allergy Awareness Month This May 3
... to reasearchers, a hormone is released into the blood after ... might be supportive in treating obesity. The reason for feeling ... hormone called PYY3-36 //which acts on the brain to produce ... report on the first human trial of PYY3-36. ...
... could be saved each year, if only everyone over the ... experts, Dr. Gregory Poland fe that universal vaccination in three ... by 40 to 50 per cent. Clearly vaccination can be ... per cent. ,Dr Poland proposes some changes to ...
... to the dimpled, 'orange peel' skin on the thighs, buttocks, ... all have a beneficial effect on the appearance of cellulite ... body's natural way of storing fat in women and occurs ... a dermatologist at the University of California, cellulite is now ...
... According to recent update, people with type 2 diabetes ... able to safely reduce their risk for heart disease ... runs counter to previous research, which showed niacin adversely ... the researchers used high doses of the medication. ...
... in lessening the symptoms of fibromyalgia.,Researchers at Pole Hospital, ... with fibromyalgia, a painful muscular condition whose causes are ... to routine sessions of graded aerobic exercise, supervised by ... of those in the exercise group rated themselves as ...
... feel, that we need to learn more about ... microwaves play an increasing role in everyday life - ... pagers, and text messengers. ,We often walk past ... other words, we are bathed in an invisible 'electrosmog', ...
Cached Medicine News:
Coat-A-Count PSA IRMA is an,immunoradiometric assay intended for the,quantitative measurement of,prostate-specific antigen (PSA) in serum,to aid in the management of prostate,cancer patient...
Stereo Smile II also includes a blank card and tests,at 60, 120, 240 and 480 sec of arc., ,Smile Test II Includes:, 1 demonstration card, 1 pair pediatric 3-D viewers, 1 pair infant 3-D v...
... and Evaluate Stereo Depth Perception ... 250 sec of arc). , ... Test (400 to 20 sec ... for Children (400 to 100 ...
The Emit 2000 Phenytoin Assay is a homogeneous enzyme immunoassay intended for use in the quantitative analysis of phenytoin in human serum or plasma. Emit 2000 assays are designed for use with most ...
Medicine Products: